Palo Alto , CA – (February 12, 2009) – Nanosys, Inc. announced today the results of their initial studies using a novel silicon nanowire mucous membrane drug delivery device. These devices have a nano-structured surface that relies on adhesive properties known in physics as van der Waals forces of adhesion. Results of initial studies published this week in the American Chemical Society’s Nano Letters, outline the device’s ability to significantly improve drug delivery to mucous membranes such as those in the nose, intestine, eyes, vagina and mouth. Mucous membranes have long been a target for drug delivery due to their large surface area and rich blood supply. However, nature has designed these membranes to also be efficient barriers to foreign substance penetration, such as drugs. Mucus, which is constantly produced by these tissues, is moved across the surface by tiny beating hair like structures called cilia. Removal of a substance floating in the mucus of the nasal cavity can be as fast as ten minutes, for example. Previous attempts at overcoming this barrier function relied on chemical modification of the delivery vehicle to better adhere to binding elements within the mucus. Nanosys’s silicon nanowires will adhere instead to the cells underneath the mucus, the actual targets for drug delivery. This critical feature allows for a longer residence time, improved local concentrations and better absorption of target drugs by the tissues.
The team, led by Hugh Daniels at Nanosys and Tejal Desai and Kayte Fischer at the University of California, San Francisco, also quantified the amount of mucosal shear force the silicon nanowire-based devices could withstand before being eliminated, and demonstrated it to be at least 100 fold better than a non-silicon nanowire device.
“In the near term, there are a lot of chronic conditions of the nose, sinuses and other tissues that could immediately benefit from more efficient delivery of currently available drugs using our silicon nanowire drug delivery technology. We are also excited about the longer term potential of delivery of systemic drugs such as insulin via the mucous membrane route,” said Dr. Daniels. In addition, silicon nanowires are inexpensive to make and are biocompatible. Nanosys expects to develop the technology further in partnership with drug manufacturers whose drugs could be made more effective through this delivery approach.
About Nanosys, Inc.
Nanosys, Inc. is a leader in the development of nanotechnology enabled products utilizing high performance inorganic nanostructures. Nanosys has built one of the broadest technology platforms in the industry with over 650 patents and patent applications covering fundamental areas of nanotechnology. Based in Palo Alto , California and privately held, Nanosys collaborates with industry leaders to develop revolutionary high-value, high-performance products for life sciences, computing, optoelectronics, renewable energy, and defense. Additional information on Nanosys can be found on its website at www.nanosysinc.com.